Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Mantle Cell Lymphoma Clinical Trials

A listing of Mantle Cell Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (11) clinical trials

Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma

PRIMARY OBJECTIVES: I. To determine the progression-free survival (PFS) rate after 2 years. SECONDARY OBJECTIVES: I. Assess toxicity. II. Determine rates of conversion from partial response (PR) to complete response (CR). III. Determine median overall survival (OS) after 4 years. TERTIARY OBJECTIVES: I. Compare minimal residual disease (MRD) results overtime ...


A clinical trial to evaluate treatments for patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle cell lymphoma

This research study is a Phase I and Ib combination clinical trial, which aims to both evaluate the safety of an investigational drug combination and also tries to define the appropriate dose of the investigational drug to evaluate in later clinical trials. "Investigational" means that the intervention is being studied. ...


A clinical trial seeking patients for a research study for the treatment of Recurrent Mycosis Fungoides/Sezary Syndrome, ESSENTIAL THROMBOCYTHEMIA, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Recurrent Childhood Lymphoblastic Lymphoma, Refractory Cytopenia With Multilineage Dysplasia, anaplastic large cell lymphoma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Refractory Anemia with Excess of Blasts, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Waldenstrom's Macroglobulinemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Childhood Myelodysplastic Syndromes, Recurrent Childhood Acute Myeloid Leukemia, chronic phase chronic myelogenous leukemia, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Relapsing Chronic Myelogenous Leukemia, Chronic myelomonocytic leukemia, Recurrent Adult T-cell Leukemia/Lymphoma, de Novo Myelodysplastic Syndromes, Childhood Chronic Myelogenous Leukemia, Myelosclerosis with myeloid metaplasia, Testicular Lymphoma, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Intraocular Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Secondary Acute Myeloid Leukemia, Hepatosplenic T-cell Lymphoma, Polycythemia Vera, Blast Crisis, T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA, Angioimmunoblastic Lymphadenopathy, Refractory Hairy Cell Leukemia, Refractory Anemia With Excess Blasts in Transformation, Refractory Multiple Myeloma, Recurrent Small Lymphocytic Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Noncutaneous Extranodal Lymphoma, Juvenile Myelomonocytic Leukemia, MALT Lymphoma, Adult Acute Myeloid Leukemia With Del(5q), Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Acute Lymphoblastic Leukemia in Remission, Post-transplant Lymphoproliferative Disorder, Small Intestine Lymphoma, Previously Treated Myelodysplastic Syndromes, Recurrent/Refractory Childhood Hodgkin Lymphoma, Childhood Burkitt Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Nodal Marginal Zone B-cell Lymphoma, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

PRIMARY OBJECTIVE: To compare the rate of disease-free survival (DFS) at 1 year post hematopoietic stem cell transplant (HSCT) in patients undergoing HSCT treated on this successor Thomas Jefferson University (TJU) 2 Step reduced intensity conditioning (RIC) haploidentical regimen and compare it with that of the initial 2 Step RIC ...


A clinical research study for the treatment of Mantle cell lymphoma

This study aims to evaluate whether the addition of lenalidomide to rituximab-maintenance improves progression free survival (PFS) compared to standard rituximab maintenance after induction treatment consisting of R-CHOP + R-HAD versus R-CHOP alone in older patients ( 60 year old) with mantle cell lymphoma. 643 patients will be randomized in ...


A clinical research study for the treatment of Mantle cell lymphoma

This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoclax vs. ibrutinib and placebo in subjects with MCL.


A clinical trial sponsored by OHSU Knight Cancer Institute for a research study for the treatment of Richter Syndrome, Waldenstrom's Macroglobulinemia, MALT Lymphoma, Night Sweats, Thrombocytopenia, Lymphadenopathy, Refractory Small Lymphocytic Lymphoma, Weight Loss, B-cell prolymphocytic leukemia, Refractory Chronic Lymphocytic Leukemia, Splenomegaly, Fever, Lymphocytosis, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Grade 3a Follicular Lymphoma, Fatigue, follicular lymphoma, Anemia, Mantle cell lymphoma, Hairy Cell Leukemia

PRIMARY OBJECTIVES: I. To evaluate the safety and tolerability of entospletinib administered in combination with obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and non-Hodgkin lymphoma (NHL), and identify the dose for phase 2 expansion. (Phase I) II. To evaluate the efficacy of entospletinib in combination with ...


A clinical trial sponsored by University of Arizona for a research study for the treatment of Juvenile Myelomonocytic Leukemia, MALT Lymphoma, Diffuse Large B-Cell Lymphoma, Acute myeloid leukemia, Burkitt's Lymphoma, Hodgkin's Disease, MYELODYSPLASTIC SYNDROME, Gray Zone Lymphoma, childhood ALL, follicular lymphoma, Chronic myeloid leukemia, Lymphoma, Preleukemia, Mantle cell lymphoma

This study will follow the standard-of-care bone marrow transplant (BMT), with the only exception being to gradually substitute post-transplant cyclophosphamide (on day +4 after BMT) with bendamustine. Three dose levels are planned for the phase I component of the study, consisting of a combination of sequentially reduced doses of cyclophosphamide ...


Patients are needed to participate in a clinical research study evaluating Onalespib for the treatment of Refractory Mantle Cell Lymphoma, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Diffuse Large B Cell Lymphoma, ALK Positive, BCL6 Positive

PRIMARY OBJECTIVES: I. Overall response rate (ORR) to single agent AT13387 (onalespib) as measured by the proportion of partial and complete responses (PR + CR) in patients with relapsed/refractory ALK positive (+) anaplastic large cell lymphoma (ALCL), mantle cell lymphoma (MCL), and BCL6+ diffuse large B cell lymphoma (DLBCL). SECONDARY ...


A clinical trial sponsored by Janssen-Cilag Ltd. for a research study of Ibrutinib

The purpose of this study is to describe the effectiveness of ibrutinib and to provide a description of ibrutinib therapy and the first non-ibrutinib subsequent therapy for chronic lymphocytic leukemia (CLL) and mantle-cell lymphoma (MCL).

Phase N/A